

## TABLE OF CONTENTS

LIST OF TABLES	xiii
LIST OF FIGURES	xxi
EXECUTIVE SUMMARY AND HIGHLIGHTS	1
<b>1. MARKET</b>	<b>11</b>
1.1 Definitions and scope	11
1.1.1 Imaging	12
1.1.2 Pathology	13
1.1.3 Health screening	15
1.2 Size	16
1.2.1 Imaging	17
1.2.2 Pathology	20
1.2.3 Genetic testing	31
1.3 Historic growth	32
1.3.1 Imaging	32
1.3.1.1 NHS organisations	32
1.3.2 Pathology	38
1.3.3 Private hospitals	38
1.4 Segmentation/funding, by payor type	39
1.5 Demand drivers	44
1.5.1 Impact of Covid	44
1.5.1.1 The overall impact of Covid on the healthcare system	44
1.5.1.2 The consequences for diagnostics	45
1.5.1.3 Covid testing	45
1.5.1.4 The impact of Covid on waiting lists for diagnostics	47
1.5.1.5 The other long-term consequences of Covid on diagnostics	48
1.6 Supply	49
1.6.1 Equipment	49
1.6.2 Staffing	49
1.7 Operating and investment models	51

1.7.1	Imaging	52
1.7.1.1	NHS contracts	53
1.7.1.2	Private hospital contracts	54
1.7.1.3	Independent imaging centres	55
1.7.1.4	High-end screening services	57
1.7.2	Image reporting	57
1.7.3	Pathology	59
1.7.3.1	NHS joint ventures/full outsourcing	60
1.7.3.2	Full service private labs	60
1.7.3.3	Private hospital outsourcing contracts	61
1.7.4	Histology reporting	61
1.7.5	Specialist labs	62
<b>2.</b>	<b>POLITICS AND REGULATION</b>	<b>65</b>
2.1	Current regulators and regulation	65
2.1.1	Care Quality Commission	65
2.1.2	Health and Safety Executive (HSE)	65
2.1.3	Ionising Radiation Medical Exposure Regulations (IRMER)	65
2.1.4	The Quality Standard for Imaging (QSI)	66
2.1.5	UKAS ISO15189	66
2.1.6	Medicines and Healthcare Products Regulatory Agency (MHRA)	66
2.1.7	Human Tissue Authority (HTA)	66
2.2	Royal colleges and professional bodies	66
2.3	Industry associations	67
2.3.1	British Institute of Radiology	67
2.3.2	British In Vitro Diagnostics Association (BIVDA)	67
2.3.3	MedTech Europe	67
<b>3.</b>	<b>PAYORS</b>	<b>69</b>
3.1	Payor groups	69
3.1.1	NHS	69
3.1.2	Local authorities	69

---

3.1.3	Private hospitals and providers	69
3.1.4	Private Medical Insurers (PMI)	69
3.1.5	Self pay but medically referred	70
3.1.6	Direct to consumer or b2c	70
3.1.7	Other payer groups	70
3.1.7.1	Occupational health	70
3.1.7.2	Paternity testing	71
3.1.7.3	Judicial testing	71
3.1.7.4	Elite sports	71
3.2.1	NHS	71
3.2.1.1	Imaging	71
3.2.1.2	Private Medical Insurers (PMI) and self-pay	74
3.2.1.3	Pathology	75
3.2.2	Local authorities	80
3.2.3	Private providers	80
3.2.3.1	Imaging	81
3.2.3.2	Pathology	81
3.2.4	Private Medical Insurers	83
3.2.5	Self-pay but medically referred	83
3.2.6	Direct to consumer	83
<b>4.</b>	<b>MAJOR PROVIDERS</b>	<b>85</b>
4.1	Market concentration by segment	85
4.1.1	Image generation	85
4.1.2	Image reporting	86
4.1.3	Pathology laboratory services	87
4.1.4	Pathology reporting	87
4.2	Economies of scale and scope	89
4.2.1	Imaging	89
4.2.2	Imaging reporting	90
4.2.3	Pathology	90
4.2.4	Pathology reporting	90

4.3	Major provider profiles	90
4.3.1	Image generation service providers	90
4.3.1.1	Alliance Medical	91
4.3.1.2	Diagnostic Healthcare	94
4.3.1.3	InHealth	97
4.3.1.4	Medical Imaging Partnership	101
4.3.1.5	Mediscan	103
4.3.1.6	Medneo	106
4.3.2	Image reporting agencies	107
4.3.2.1	4Ways	107
4.3.2.2	DMC Healthcare (fka Dulwich Medical Centre)	110
4.3.2.3	Everlight Radiology	111
4.3.2.4	Medica plc	113
4.3.2.5	Radnet	115
4.3.2.6	Unilabs plc	116
4.3.3	Laboratory service providers	119
4.3.3.1	Alderly Lighthouse Laboratory	119
4.3.3.2	Check4Cancer	120
4.3.3.3	Eurofins Biomnis	121
4.3.3.4	FlouretiQ	125
4.3.3.5	London Medical Laboratory	126
4.3.3.6	Nationwide Pathology	127
4.3.3.7	Medilims	128
4.3.3.8	Melio	129
4.3.3.9	Micropathology	130
4.3.3.10	Numan	131
4.3.3.11	Prenetics	132
4.3.3.12	Serco/Synnovis	133
4.3.3.13	Sonic Healthcare (through UK subsidiary The Doctors Laboratory)	136
4.3.3.14	Synlab	137
4.3.3.15	Thriva	141

---

4.3.3.16	Truepill	142
4.3.3.17	Xyla Diagnostics	143
4.3.4	Major international diagnostic service companies not currently present in the UK	144
4.3.4.1	Affidea	144
4.3.4.2	Alab	146
4.3.4.3	Amedes	147
4.3.4.4	Canon Medical Systems	150
4.3.4.5	LabCorp	151
4.3.4.6	Limbach Group	156
4.3.4.7	Medicover	157
4.3.4.8	Quest Diagnostics	159
<b>5.</b>	<b>KEY SUPPLIERS TO THE MARKET</b>	<b>165</b>
5.1	Major imaging suppliers	165
5.1.1	Canon	165
5.1.2	GE Healthcare	168
5.1.3	Hitachi	174
5.1.4	Philips	176
5.1.5	Siemens	181
5.2	Pathology	186
5.2.1	Major full laboratory/managed equipment service providers	186
5.2.1.1	Abbott	186
5.2.1.2	Beckman Coulter	188
5.2.1.3	Roche	190
5.2.2	Histopathology reporting service providers	194
5.2.2.1	Backlogs (part of HCA Laboratories)	194
5.2.2.2	Cellular Pathology Services	195
5.2.2.3	Diagnexia	196
5.2.2.4	Digital Pathology Partners	197
5.2.2.5	Pathgnomics (Cytel)	198
5.2.2.6	Poundbury Cancer Institute	199

---

5.2.2.7	Source Bioscience	200
5.2.3	Other significant laboratory suppliers	204
5.2.3.1	Agilent (niche products including mass spectrometry)	204
5.2.3.2	Becton Dickinson (sample collection systems, cytology systems, microbiology automation)	208
5.2.3.3	bioMérieux (Microbiology products)	215
5.2.3.4	Illumina (genetic sequencing)	217
5.2.3.5	Oxford Nanopore	219
5.2.3.6	Roper Technologies	220
5.2.3.7	Sysmex (haematology products)	223
5.2.3.8	Thermo Fisher Scientific	226
5.4	Diagnostic software/IT providers	233
5.4.1	Citadel Health	233
5.4.2	Dedalus	234
5.4.3	Xlab	235
<b>6.</b>	<b>INVESTORS</b>	<b>237</b>
6.1	Investors involved in the sector and their portfolios	237
6.2	Overseas quoted groups	237
6.2.1	Life Healthcare	237
6.2.2	Sonic Group	237
6.2.3	Synlab	237
6.2	Private equity funds and their portfolios	238
6.2.1	Apax	238
6.2.2	A.P. Moller Holding	238
6.2.3	Apposite Capital	238
6.2.4	Cinven	239
6.2.5	ECI Partners	239
6.2.6	Livingbridge	239
6.2.7	Seneca Partners Home	240
6.2.8	Synova	240
6.3	Major International diagnostic service groups not currently involved in the	

---

UK diagnostic market	240
6.3.1 Affidea	240
6.3.2 Alab	241
6.3.3 Amedes	241
6.3.4 LabCorp	241
6.3.5 Medcover	241
6.3.6 Quest	242
6.4 Exits, entries, acquisitions and other key events	242
<b>7. MARKET POTENTIAL</b>	<b>245</b>
7.1 Future need, prospects	245
7.2 New technology	245
7.2.1 Genomic testing	246
7.2.1.1 BGI Genomics (China)	247
7.2.1.2 Centogene	247
7.2.1.3 Exact Sciences	247
7.2.1.4 Foundation Medicine	248
7.2.1.5 Grail	248
7.2.1.6 Guardant	248
7.2.1.7 Helix	249
7.2.1.8 Illumina	249
7.2.1.9 Myriad Genetics	249
7.2.1.10 Natera	249
7.2.1.11 Sema4	250
7.2.1.12 Agendia	250
7.2.1.13 Biotheranostics	250
7.2.1.14 Exosome Diagnostics	251
7.2.1.15 Inivata	251
7.2.1.16 MDx Healthcare	251
7.2.1.17 MLL (Munich Leukaemia Laboratory)	251
7.2.1.18 Nanostring Technologies	252
7.2.1.19 NIMGenetics Spain	252


7.2.1.20	Omniseq	252
7.2.1.21	Oncologica UK	252
7.2.1.22	OncoDNA	253
7.2.1.23	Oxford Cancer Biomarkers (OCB)	253
7.2.1.24	Personal Genome Diagnostics	253
7.2.1.25	Veracyte	253
7.2.1.26	Eurofins	254
7.2.1.27	LabCorp (US)	254
7.2.1.28	Quest (US)	254
7.2.1.29	Sonic (TDL parent)	254
7.2.1.30	Source Bioscience	255
7.2.1.31	Synlab	255
7.2.2	Digital histology	255
7.2.3	Artificial Intelligence (AI)	256
7.2.3.1	Aidance	256
7.2.3.2	Behold AI	257
7.2.3.3	Google	257
7.2.3.4	Kheiron Medical	257
7.2.3.5	Qure	257
7.2.3.6	Signify Research	258
7.2.3.7	Ibex	258
7.2.4	Other innovative technology	258
7.2.4.1	Healthy.io	258
7.2.4.2	Vitestro Vitestro	259
7.3	International comparisons	259
7.4	Market volume, pricing and value forecasts	269
7.4.1	Demographics	270
7.4.2	Macro economics	270
7.4.3	NHS policy/post-Covid recovery	270
7.4.4	Developments in AI and medical technology	270
7.4.5	Consumerism	270



7.5.6	Employer attitude to benefits/PMI	271
7.5.7	Medical practice	271
7.6	Conclusions	271
<b>APPENDIX 1. GLOSSARY</b>		<b>273</b>
<b>APPENDIX 2. REGULATORS</b>		<b>277</b>
<b>APPENDIX 3. TRADE BODIES AND ASSOCIATIONS</b>		<b>279</b>



## Print - Online - Digital - Mobile



Healthcare Markets UK is the leading journal covering the UK independent healthcare sector. Drawing upon LaingBuisson's unique data, the title combines high-quality journalism with in-depth analysis and contributions from key industry associations and sector experts. Digital and print subscriptions include access to an online archive dating back to 1998.

For further information on these titles visit [laingbuissonnews.com](http://laingbuissonnews.com) where you can sign up for a trial, or contact our account managers on [sales@laingbuisson.com](mailto:sales@laingbuisson.com) or +44 (0)20 7841 0045

*Independent.  
Intelligent.  
Insightful.*

- Ten print editions** - delivered through the year
- News insight** - taking stories beyond the headlines
- In depth features** - written by authors with a deep understanding of the markets
- Interviews** - with leading healthcare figures
- Unique data tables** - presenting LaingBuisson figures on market sizes
- Special supplements** - including roundtable reports, cost surveys, infographic posters
- Online archive** - news and features dating back well over a decade
- News e-alerts** - delivered to your inbox

### Additional subscriber benefits

- Early registration window** for LaingBuisson conferences and seminars, with fixed 'early bird' rate
- 5% discount** on all additional LaingBuisson product or event purchases made throughout your subscription

## Subscribe now

Subscribe to a single printed hard copy title for just **£499** a year, or upgrade to receive print and digital copies for **£749\***, or take out a subscription to both **Healthcare Markets and Care Markets** and pay just **£749** for print and **£999\*** for the digital package.

**Company-wide subscription packages also available including multiple print copies and online subscription accounts - call to discuss prices.**

## LIST OF TABLES

Table ES1	'Wholesale' imaging market, £m, UK, 2021 (cost to hospitals of providing/outsourcing services)	2
Table ES2	'Wholesale' pathology market, £m, UK, 2021 (cost to hospitals of providing/outsourcing services)	3
Table 1.1	National screening programmes, England, 2020/21	16
Table 1.2	Diagnostic market, £m, UK, 2021	17
Table 1.3	Volume of images/scans (000s) by modality, UK, 2021 (est.)	18
Table 1.4	Proportion of images generated by in-house vs. outsourced to imaging companies, 2021	19
Table 1.5	Reporting of NHS images (000s) for NHS organisations, 2021/22 (est.)	20
Table 1.6	'Wholesale' volume and value of image generation market, 2021	21
Table 1.7	Reporting of images (000s) market value, 2021	22
Table 1.8	Consultant radiologist primary and secondary interest, 2018	23
Table 1.9	NHS and private pathology test volumes, number of tests undertaken in laboratories (millions), UK, 2021/22	24
Table 1.10a	Number of NHS tests (millions) split between direct access (GP requested) and hospital, UK, 2021/22 (est.)	24
Table 1.10b	NHS pathology test volumes (millions) and cost, £m, 2021 (est.)	25
Table 1.11	NHS and private pathology values, cost/value of tests, £m, UK, 2021 (est.)	26
Table 1.12	NHS lab costs (including outsourced), £m, and staffing, 2021	27
Table 1.13	NHS biochemistry tests, UK, 2021 (est.)	27
Table 1.14	NHS haematology tests, UK, 2021	29
Table 1.15	NHS immunology tests, UK, 2021	29
Table 1.16	NHS microbiology tests, UK, 2021	30
Table 1.17	NHS cellular pathology tests, UK, 2021	30
Table 1.18	NHS organisations scans (000s) by modality, UK, 2012–2021	32
Table 1.19	Private hospital/clinic image generation (000s) by modality, UK, 2012–2021	34
Table 1.20	NHS radiology tariffs (examples of high volume images), £ nominal, 2012/13–2020/21	35
Table 1.21a	NHS organisations reporting by modality, 000s, UK, 2012–2021	36
Table 1.21b	NHS organisation average cost of reporting per scan by modality, £ nominal, 2012–2021	36
Table 1.21c	NHS organisation value of reporting per scan by modality, £m (nominal), 2012–2021	37
Table 1.22	Private hospitals/clinics and PPU, reporting by modality, 000s, UK, 2012–21	37
Table 1.23	NHS hospital pathology test volumes, millions, UK, 2012–21	38
Table 1.24	Private hospital/clinic pathology test volumes, millions, UK, 2012–21	39

Table 1.25	Retail market, by payor, £m, 2021	41
Table 1.26	Self-pay rates in private hospitals and clinics, £ per scan, 2021	42
Table 1.27	Typical imaging rates paid by PMI to private hospitals, £ per scan, 2021	42
Table 1.28	Typical pathology rates paid by PMI to private hospitals, £ per test, 2021	43
Table 1.29	Covid testing, million tests per quarter, UK, 2020–2022	46
Table 1.30	Average tests per day, 000s, UK, 2020–2022	46
Table 1.31	NHS England patients waiting over 13 weeks for diagnostic tests, UK, 2018–2022	48
Table 1.32	Radiologists employed in the NHS, UK, 2014–2021	51
Table 3.1	Medica reporting prices, £ nominal/scan, 2013–2018	72
Table 4.1	Image generation market shares, £m, 2021 (est.)	85
Table 4.2	Image generation market, estimated market shares, %, 2021 (est.)	85
Table 4.3	Image reporting market shares, £m and market share %, 2021	86
Table 4.4	Pathology laboratory services revenues by segment, £m, 2021	87
Table 4.5	Laboratory company and subsidiary/JV company accounts, £000s, 2018–21	88
Table 4.6	Histopathology reporting market shares, £m and %, 2021	89
Table 6.1	Diagnostic market key events, 2007–2022	242
Table 7.1a	MRI scans per 1,000 population (ranked by 2019 to avoid Covid distortions)	261
Table 7.1b	MRI scanners per million population (ranked by 2019 to avoid Covid distortions)	262
Table 7.2a	CT scans per 100 population (ranked by 2019 to avoid Covid distortions)	264
Table 7.2b	CT scanners per million population (ranked by 2019 to avoid Covid distortions)	265
Table 7.3	PET CT Scans per 1,000 population (ranked by 2017)	267
Table 7.4	Imaging equipment utilisation, ranked by MRI	268
Table 7.5	Diagnostic consultants per 100,000 citizens	269

## LIST OF FIGURES

Figure ES1	Imaging market, UK	2
Figure ES2	Pathology market, UK	3
Figure 1.1	NHS lab costs (including outsourcing), UK, 2021 (est.)	26
Figure 1.2	NHS organisations scans (000s) per modality, UK, 2021/22	33
Figure 1.3	Private hospital/clinic image generation (000s) by modality, UK, 2021	33
Figure 3.1	Use of commercial image reporting companies by NHS organisations, 2021/22 (and 2017/18)	74
Figure 3.2	Spend with consultants and commercial reporting companies, 2021/22 (and 2017/18)	74
Figure 3.3	NHS England CCG methods of paying for GP Direct Access pathology, 2021/22 (and 2017/18)	77
Figure 3.4	Models used by Trusts for reporting excess histology demand, 2021/22 (and 2017/18)	79
Figure 3.4b	...of those trusts using commercial companies, their spending in the last year, 2021/22 (and 2017/18)	79
Figure 4.1	Image reporting market, £m, 2021	86
Figure 7.1a	MRI scans per 1,000 population, 2020	263
Figure 7.1b	MRI scans per million population, 2020	263
Figure 7.2a	CT scans per 100 population, 2020	266
Figure 7.2b	CT scanners per million population, 2020	267
Figure 7.3	PET CT Scans per 1,000 population, 2017	268

# Do you want to understand the global healthcare market?



**Healthcare Markets *international***, the latest journal from business intelligence provider LaingBuisson, delivers comprehensive, reliable and independent reporting on the full range of acute and primary healthcare services markets operating around the world. This digital journal covers medical and surgical hospitals and clinics, psychiatric hospitals, fertility, dentistry, primary healthcare and temporary/flexible staffing. Embracing the latest business activities across the healthcare sector, HMI delivers interviews with leading names in the sector, in-depth features and business news coverage, providing invaluable insight and analysis.

## SUBSCRIBE NOW

An annual digital subscription is just £749 and provides you with online access to the latest market intelligence, ten PDF issues and a subscription to the International Medical Travel Journal.

+44 (0)20 7841 0045  
sales@laingbuisson.com  
laingbuissonnews.com

**REQUEST YOUR FREE TRIAL TODAY**

To find out more visit [www.laingbuissonnews.com](http://www.laingbuissonnews.com)